It would be more promising if olaparib had demonstrated its superior efficacy in DDX11-overexpressed ccRCC compared to DDX11-downexpressed ccRCC, because the use of olaparib would not be limited to non-aggressive ccRCC patients, who have fewer options for targeted therapy compared to those with aggressive ccRCC. This evidence concerns the gene DDX11 and nonpapillary renal cell carcinoma.